This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PRKG1 / cGMP-dependent protein kinase 1 · IHC design guide
Design Immunohistochemistry for PRKG1
Plan PRKG1 chromogenic IHC in paraffin sections using the catalog antibody's 2–5 μg/mL dilution range (datasheet A01708-3). Use the cytoplasmic tissue pattern and medium staining in adipocytes to guide assessment (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PRKG1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | General cytoplasmic staining (HPA tissue IHC) | |
| Staining pattern | Medium cytoplasmic staining in adipocytes (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A01708-3) | |
| Positive control | Adipose tissue+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01708-3) | |
| Caveat | Antibody staining and RNA show medium consistency (HPA tissue IHC) | |
| Regulation | Primarily expressed in lung and placenta (UniProt) | |
| Isoform / epitope | 3 isoforms; check antibody epitope coverage (UniProt) |
Section 1
Recommended PRKG1 IHC & IF Protocols
The catalog antibody uses EDTA retrieval for IHC on paraffin sections (datasheet: A01708-3). Three published PRKG1 IHC protocols provide additional conditions (PMC13446705; PMC7454216; PMC8131144).
| Sample | Paraffin-embedded mouse lung tissue; fixative not specified (datasheet A01708-3) |
| Fixation | Image fixative and duration unreported (datasheet A01708-3); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A01708-3); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A01708-3) |
| Primary antibody | Rabbit anti-PRKG1, 2-5μg/ml (datasheet A01708-3) |
| Primary incubation | Overnight at 4 °C (datasheet A01708-3) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A01708-3) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PRKG1-positive staining in adipocytes of adipose tissue (HPA tissue IHC: Medium). HPA tissue profile: General cytoplasmic expression. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA at pH 8.0 for the catalog antibody (datasheet: A01708-3); compare citrate at pH 6.0 for paraffin sections if needed (PMC13446705: methods).
Section 2
What Is the Expected PRKG1 Staining Pattern?
PRKG1 should appear mainly in the cytoplasm (UniProt Q13976: cytoplasm; HPA tissue IHC: general cytoplasmic expression). HPA reports medium staining in adipocytes, respiratory epithelial cells, glial cells, and several other sampled cell types (HPA tissue IHC). Its tissue IHC profile is rated Enhanced, with medium consistency between staining and RNA expression (HPA tissue IHC: reliability). PRKG1 has no transmembrane segment (UniProt Q13976: topology).
| Cytoplasmic chromogen in adipocytes or bronchial respiratory epithelial cells, with discernible cell boundaries. | This fits the reported compartment and sampled cell types; HPA rates each example Medium (HPA tissue IHC: profile; positive tissues). Judge intensity against the chosen tissue and its negative control, since staining alone does not establish antibody specificity (general IHC practice). |
| Predominantly nuclear staining, with little discernible cytoplasmic signal. | A nuclear dominant pattern conflicts with the reported cytoplasmic IHC profile (HPA tissue IHC: profile). Consider nonspecific binding, counterstain confusion, or detection artefact (general IHC practice). Recheck compartment assignment before scoring cells as PRKG1 positive. |
| Strong staining confined to a cell population outside the expected pattern for the sampled tissue. | Question cross-reactivity or endogenous detection activity (general IHC practice). HPA reports particular sampled cell types, but its empty negative list does not prove other cells lack PRKG1 (HPA tissue IHC: positive and negative lists). Confirm cell identity and compare controls before calling a new pattern. |
| Diffuse chromogen over cells and extracellular areas, obscuring cell boundaries. | The distribution cannot be confidently assigned to cytoplasm (HPA tissue IHC: profile). Excess background can arise from detection activity or insufficient blocking or washing (general IHC practice); interpret the tissue only after a negative control shows whether the haze depends on primary antibody. |
| No cytoplasmic signal in a reported Medium tissue and cell type. | For example, absent adipocyte staining falls short of the HPA observation (HPA tissue IHC: adipose tissue, Medium). Check that the expected cells are present, then assess the run controls and antibody conditions (general IHC practice). A failed run cannot establish biological absence. |
💡Expected PRKG1 appearanceCall the result positive when cells show discernible cytoplasmic staining, typically Medium in the HPA listed positive examples (HPA tissue IHC: profile; positive tissues); isolated nuclear signal or boundary obscuring haze is suspect (HPA tissue IHC: profile; general IHC practice).
| Compartment and membrane association | PRKG1 is cytoplasmic and lacks a transmembrane segment (UniProt Q13976: subcellular location; topology). UniProt also notes colocalization with TRPC7 at the plasma membrane; a possible edge associated signal should therefore be evaluated alongside the cytoplasmic pattern, rather than treated as proof of a membrane spanning protein (UniProt Q13976: subcellular location). |
| Tissue and cell context | HPA records Medium staining in adipocytes, adrenal and breast glandular cells, bronchial respiratory epithelial cells, caudate glial cells, and cerebellar granular layer cells (HPA tissue IHC: positive tissues). It records Low staining in salivary glandular, bladder urothelial, and vaginal squamous epithelial cells (HPA tissue IHC: low tissues). These are observations, not universal negative controls. |
| Antibody evidence | HPA lists HPA007699 as IHC Approved and CAB009629 as IHC Enhanced (HPA antibodies). The overall tissue profile is Enhanced but has medium staining to RNA consistency (HPA tissue IHC: reliability). Record the actual antibody used when comparing images; a validation label does not resolve every ambiguous cell or compartment (general IHC practice). |
| Isoforms and processing | UniProt lists three isoforms, Alpha, Beta, and 3, and no signal peptide or propeptide (UniProt Q13976: isoforms; processing). An antibody's isoform coverage depends on its mapped epitope; no epitope information is supplied here, so the staining cannot be assigned to an individual isoform. |
| IF/ICC Q: What pattern should I expect? | A: HPA reports approved cytosol and vesicle localisation in ICC-IF images from HEK293, U-251MG, and U2OS (HPA subcellular; cell lines). That IF observation can help assess compartment plausibility, while paraffin section IHC remains the application addressed here. |
| Antigen retrieval | Retrieval conditions can affect chromogenic IHC generally (general IHC practice). The supplied HPA and UniProt records give no PRKG1 specific retrieval or fixation sensitivity, so optimize against a reported positive tissue and controls without attributing a change to a documented PRKG1 fixation effect. |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected cytoplasmic staining is absent in a reported positive sample. | The expected cell population may be missing, or the staining run may have failed (HPA tissue IHC: positive tissues; general IHC practice). | Verify cell identity on the section; inspect positive and negative run controls, then review the antibody dilution, retrieval, and detection steps as general IHC checks (general IHC practice). Do not infer PRKG1 absence from one failed section. |
| Nuclei stain more strongly than cytoplasm. | That pattern disagrees with the general cytoplasmic IHC profile (HPA tissue IHC: profile); nonspecific staining or counterstain confusion is possible (general IHC practice). | Compare the primary omitted control and counterstain, then reassess staining within cell boundaries (general IHC practice). Report unresolved nuclear dominant staining as atypical, rather than scoring it as the expected PRKG1 pattern. |
| Low level urothelial or squamous staining is called a failed positive. | HPA records Low staining in bladder urothelial and vaginal squamous epithelial cells (HPA tissue IHC: low tissues). | Use a tissue and cell type reported as Medium for the positive comparison, such as adipocytes or bronchial respiratory epithelium (HPA tissue IHC: positive tissues). Keep the Low observation distinct from an absent signal. |
| Broad haze or staining persists when the primary antibody is omitted. | Primary independent chromogen may reflect endogenous detection activity or background from detection reagents (general IHC practice). | Check the detection chemistry and appropriate blocking and washing controls for the tissue (general IHC practice). Reassess PRKG1 localisation only after cell boundaries and cytoplasm are readable. |
| An unexpected cell population stains strongly. | Cross-reactivity or detection background is possible (general IHC practice), while HPA provides no confirmed negative cell list for this record (HPA tissue IHC: negative list). | Confirm tissue anatomy and cell identity; compare a primary omitted control and, where available, staining with an independently validated antibody (general IHC practice; HPA antibodies). Describe unresolved staining as unexpected, not definitively false. |
| Two antibodies produce different cellular patterns. | Their HPA IHC statuses differ, and epitope coverage is unspecified here (HPA antibodies; UniProt Q13976: isoforms). | Record each antibody identity and compare the same compartment, tissue cells, and run controls (general IHC practice). Prefer conclusions supported by the cytoplasmic HPA profile; do not assign the discrepancy to an isoform without epitope evidence. |
Experiment evidence
IHC & IF images showing PRKG1 staining
A01708-3 · IHCIHC analysis of CGKI/PRKG1 using anti-CGKI/PRKG1 antibody (A01708-3). CGKI/PRKG1 was detected in paraffin-embedded section of mouse lung tis
A01708-3 · IHCIHC analysis of CGKI/PRKG1 using anti-CGKI/PRKG1 antibody (A01708-3). CGKI/PRKG1 was detected in paraffin-embedded section of rat lung tissu
A01708-3 · IFIF analysis of CGKI/PRKG1 using anti-CGKI/PRKG1 antibody (A01708-3). CGKI/PRKG1 was detected in immunocytochemical section of U20S cells. En
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185532-PRKG1/tissue/cerebral+cortex#imid_2631716
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185532-PRKG1/tissue/colon#imid_2631650
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185532-PRKG1/tissue/liver#imid_2631635
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185532-PRKG1/tissue/kidney#imid_2631636
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA007699; green = PRKG1, blue = nucleus, red = microtubules.
HPA · ICC-IF HEK293Human Protein Atlas immunofluorescence, HEK293, antibody HPA007699; green = PRKG1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PRKG1 IHC & IF
🧪Run adipose tissue first and assess staining in adipocytes, which HPA scores as Medium (HPA: adipose tissue, adipocytes, Medium). HPA detects PRKG1 in all 45 scored tissues, so use no-primary and isotype controls in place of a negative tissue; other cells on the positive slide should be assessed for background, but the supplied HPA rows do not establish them as target-negative (HPA: no negative rows; detected in all 45 scored tissues).
Positive control tissue: Adipose tissue (Adipocytes, HPA Medium)
Negative control tissue: None in HPA: PRKG1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PRKG1 in HEK293, U-251MG, U2OS, with annotated localisation: Vesicles (approved), Cytosol (approved) (HPA subcellular).
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG isotype control for the caption’s rabbit primary antibody; a PRKG1 knockout specimen or validated peptide block can provide a biological specificity control (caption: rabbit anti-PRKG1; standard IHC practice). Quench endogenous peroxidase and check endogenous biotin background when using the caption’s biotin-based SABC and DAB detection on adipose tissue (caption: biotinylated secondary, SABC, DAB; standard IHC practice).
⚠️Feasibility: The selected A01708-3 mouse lung paraffin-section caption does not report a fixative, and the supplied evidence reports no PRKG1-specific fixation window or fixation effect (caption: fixative unreported). That caption uses heat retrieval in EDTA at pH 8.0, but does not establish that retrieval is required for every specimen (caption: EDTA heat retrieval). HPA has ICC-IF images in HEK293, U-251MG and U2OS cells, but the supplied evidence does not establish that frozen sections or IF are easier; in adipose sections, lipid spaces and tissue background warrant morphology-based interpretation (HPA: ICC-IF cell lines; standard IHC practice).
HPA tissue IHC evidence for PRKG1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Enhanced — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Medium | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
| Appendix | Lymphoid tissue | Medium | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Medium | Protein (IHC) | HPA → |
| Breast | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: PRKG1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced PRKG1 IHC Tips
Troubleshoot PRKG1 staining in paraffin sections by checking retrieval, tissue preservation, cellular localisation, controls and scoring before interpreting chromogenic signal.
Which retrieval condition should I start with for PRKG1 paraffin-section IHC?
Use heat-mediated antigen retrieval in EDTA buffer at pH 8.0 for PRKG1 paraffin-section IHC (datasheet A01708-3). This condition was used for mouse lung sections stained with 2 μg/ml catalog antibody after 10% goat-serum blocking and overnight incubation at 4°C (datasheet A01708-3). Compare adjacent sections under the same heating and cooling conditions, then assess morphology alongside staining intensity (standard IHC practice). If staining remains weak, titrate heating duration while keeping the documented EDTA condition as the reference, because excessive retrieval can damage sections or increase background (standard IHC practice). Record each change so differences in staining can be attributed to retrieval rather than detection conditions (standard IHC practice).
How should I assess whether fixation is affecting PRKG1 staining?
The mouse lung paraffin-section caption does not state a fixative, so PRKG1-specific fixation sensitivity is unknown (datasheet A01708-3). Record the fixative and processing history for each specimen, and compare sections prepared under matched conditions before attributing staining differences to PRKG1 abundance (standard IHC practice). Include a consistently processed positive-control section and a no-primary control in each run to distinguish variable antigen detection from background (standard IHC practice). If fixation history differs across samples, assess tissue preservation and staining consistency before comparing signal intensity (standard IHC practice). Neither the reported tissue-staining pattern nor PRKG1 topology establishes how this antibody responds to a particular fixation duration (HPA: tissue IHC; UniProt Q13976 topology).
Which PRKG1 staining pattern should I expect in tissue sections?
Assess PRKG1 primarily as a cytoplasmic signal: tissue IHC shows general cytoplasmic expression, while subcellular imaging places it in cytosol and vesicles (HPA: tissue IHC; HPA: subcellular). PRKG1 has no transmembrane segment, although it can colocalize with TRPC7 at the plasma membrane (UniProt Q13976 topology and subcellular location). Score the cytoplasmic compartment separately from nuclear, stromal and extracellular staining so each pattern remains interpretable (standard IHC practice). A faint membrane-associated component can be assessed in cellular context, but an exclusively sharp membrane outline needs independent validation before assignment to PRKG1 (UniProt Q13976 subcellular location; standard IHC practice). Compare suspicious patterns with a no-primary section and intact neighbouring cells (standard IHC practice).
Can this stain distinguish PRKG1 isoforms or modified epitopes?
PRKG1 has 3 reported isoforms, Alpha, Beta and 3, but the supplied antibody caption does not identify its epitope or establish isoform selectivity (UniProt Q13976 isoforms; datasheet A01708-3). The protein kinase region spans residues 360–619, and the AGC kinase C-terminal region spans 620–671 (UniProt Q13976 domains). Report this chromogenic signal as PRKG1 unless an epitope map or isoform-specific validation supports a narrower claim (standard IHC interpretation). Documented modified residues include phosphothreonine at 59 and 515, but their presence does not establish whether this antibody detects phosphorylation-dependent staining (UniProt Q13976 modified residues; datasheet A01708-3). Test any proposed isoform or modification interpretation with independently validated reagents on matched sections (standard IHC practice).
How can I follow up an IHC pattern with PRKG1 immunofluorescence?
Use the chromogenic IHC pattern to select regions for a separate IF experiment; the supplied paraffin-section caption establishes IHC processing, not IF performance (datasheet A01708-3). Multiplex PRKG1 with a validated ACTA2 marker when evaluating smooth muscle cells, since ACTA2 occurs in a reported PRKG1 signalling complex (UniProt Q13976 subunit; standard IF practice). Choose spectrally separated fluorophores and inspect unstained tissue for autofluorescence before assigning a faint channel to PRKG1 (standard IF practice). Because PRKG1 is cytoplasmic and lacks a transmembrane segment, assess permeabilisation for access to an intracellular epitope; the antibody’s precise epitope remains unspecified (UniProt Q13976 subcellular location and topology; datasheet A01708-3). Include single-label and no-primary controls when assessing colocalisation (standard IF practice).
What should I check when PRKG1 DAB staining is diffuse?
The documented mouse lung workflow used 10% goat-serum blocking, a biotinylated secondary antibody, a streptavidin-biotin complex and DAB (datasheet A01708-3). Check a no-primary section for background from detection reagents, including endogenous peroxidase or biotin, before changing the PRKG1 antibody concentration (standard IHC practice). Apply an appropriate peroxidase block and, if needed, a biotin-control strategy as general chromogenic IHC steps, then compare matched sections (standard IHC practice). Inspect tissue edges and folds separately because reagent pooling or damaged morphology can mimic strong staining (standard IHC practice). Retain the documented 2 μg/ml antibody condition as the comparison point when titrating primary antibody or detection exposure (datasheet A01708-3; standard IHC practice).
How should I quantify PRKG1 chromogenic staining across sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the tissue region and cell population before scoring, then record cytoplasmic PRKG1 staining separately from other compartments (HPA: general cytoplasmic expression; standard IHC practice). For identified cells, report the percentage positive and an H-score based on intensity categories; keep thresholds and counterstain settings consistent across sections (standard IHC practice). For a spatial analysis, report positive-cell density per mm² of evaluable tissue and exclude folds, necrosis and poorly preserved areas by the same rules (standard IHC practice). Normalise cell-based measurements to the number of eligible cells and area-based measurements to analysed tissue area, with the sampled cell type stated (standard IHC practice). Assess controls before comparing batches (standard IHC practice).
How do I distinguish credible PRKG1 staining from artefact?
A credible PRKG1 result should be evaluated in the expected cytoplasmic compartment and in identifiable cells, alongside matched controls (HPA: general cytoplasmic expression; standard IHC practice). The documented mouse lung paraffin-section image provides a tissue reference, while reported expression in blood-vessel-associated tissue supports examining vascular cells in their histological context (datasheet A01708-3; HPA: tissue-enhanced RNA specificity, Blood vessel). Treat staining confined to section edges, folds or necrotic regions as suspect until intact regions show the same pattern (standard IHC practice). Check a no-primary section for endogenous peroxidase or biotin-related DAB signal, particularly with the documented biotin-based detection workflow (datasheet A01708-3; standard IHC practice). Do not interpret staining intensity alone as kinase activity (UniProt Q13976 function; standard IHC interpretation).
Boster reagents
Best PRKG1 / cGMP-dependent protein kinase 1 IHC Antibodies
A01708-3 has IHC images from paraffin sections of mouse and rat lung and human breast cancer, plus an IF image from U20S cells (A01708-3 image captions).
Real IHC data
Anti-cGKI/PRKG1 Antibody ®
Cat # A01708-3
A01708-3 lists IHC, IF, and ICC applications and human, mouse, and rat reactivity (catalog applications; catalog reactivity). Its images show paraffin-section IHC in mouse and rat lung and human breast cancer, and IF in U20S cells (A01708-3 image captions).
Which to pick: For tissue IHC, choose A01708-3: its images document paraffin sections with EDTA pH 8 retrieval; the fixative is unreported (A01708-3 IHC image captions). For IF/ICC, A01708-3 lists both applications and has a U20S cell IF image (catalog applications; A01708-3 IF image caption). For cross-species IHC, A01708-3 lists human, mouse, and rat reactivity and has IHC images from all three; clonality is unreported (catalog reactivity; A01708-3 IHC image captions; catalog clone field).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q13976 (KGP1_HUMAN, cGMP-dependent protein kinase 1).
- Human Protein Atlas. PRKG1 tissue IHC expression (reliability: Enhanced).
- Human Protein Atlas. PRKG1 subcellular location (ICC-IF): Localized to vesicles and cytosol..
- Human Protein Atlas. PRKG1 antibody validation summary (2 antibodies).
- Vitamin B12 combined with methylene blue alleviates experimental septic shock and is associated with modulation of KCNMB1 and the cGMP-PRKG pathway. PloS one 2026 — PMC13446705.
- Upregulation of cGMP-dependent Protein Kinase (PRKG1) in the Development of Adolescent Idiopathic Scoliosis. Orthopaedic surgery 2020 — PMC7454216.
- cGMP-dependent protein kinase type I is implicated in the regulation of the timing and quality of sleep and wakefulness. PloS one 2009 — PMC2617781.
- Network Pharmacology Prediction and Pharmacological Verification Mechanism of Yeju Jiangya Decoction on Hypertension. Evidence-based complementary and alternative medicine : eCAM 2021 — PMC8131144.
- PubMed PMID:2792381 — UniProt-cited evidence.
- PubMed PMID:8613202 — UniProt-cited evidence.
- PubMed PMID:9192852 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PRKG1 (cGMP-dependent protein kinase 1). Expected localisation General cytoplasmic staining (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A01708-3). Validated IHC antibody: A01708-3 at 2-5μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Adipose tissue (Adipocytes); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded mouse lung tissue; fixative not specified (datasheet A01708-3); 2. Fixation: Image fixative and duration unreported (datasheet A01708-3); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A01708-3); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A01708-3); 8. Primary antibody: Rabbit anti-PRKG1, 2-5μg/ml (datasheet A01708-3); 9. Primary incubation: Overnight at 4 °C (datasheet A01708-3). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A01708-3); Caveat: Antibody staining and RNA show medium consistency (HPA tissue IHC); Isoform / epitope: 3 isoforms; check antibody epitope coverage (UniProt); Regulation: Primarily expressed in lung and placenta (UniProt). Evidence: UniProt Q13976, HPA tissue IHC · Enhanced, HPA ICC-IF · vesicles and cytosol., Datasheet A01708-3, PMC13446705, PMC7454216. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PRKG1/immunohistochemistry-ihc-guide.